A possible novel pharmacological therapy for Parkinson's disease using the pleiotropic property of Selegiline

Shin Ichi Ono, Ryuji Sorte, Ei Ichi Tokuda

Research output: Contribution to journalArticle

Abstract

Monoamine oxidase type B (MAO-B) inhibitors have neuroprotective properties in addition to their primary pharmacologic function. We examined the effects of selegiline, an irreversible MAO-B inhibitor, on the expression levels of survivin mRNA and lipid peroxidation in the corpus striata of 1-methyl-4-phenyl 1,2,3,6 tetrahydropyridine (MPTP)-induccd Parkinsonian roice. Mice were treated with normal saline (vehicle as control), MPTP alone (30 mg/kg of body weight), MPTP with low-dose of selegiline (0-1 mg/kg of body weight), or MPTP with high-dose of selegiline (1.0 mg/kg of body weight). A consecutive 7-day oral treatment of MPTP alone d'd not influence survivin mRNA expression. Selegiline treatment together with MPTP significantly uprcgulated survivin expression at both low- and high-doses. Interestingly, lipid Peroxidation was significantly suppressed by a low-dose of selegiline but not by a high-dose. These results suggest that selegiline has Pleiotropic effects; the upregulation effects on survivin mRNA expression are likely to be '"dependent from its primary pharmacological Properties (MAO-B inhibition), whereas the inhibitory effects on lipid peroxidation seem to be associated with its primary pharmacological properties. In addition to conventional dopamine supplementation therapy, selegiline might serve as a novel pharmacological therapeutic strategy for Parkinson's disease through its antiapoptotic properties via survivin induction as well as its antioxidative properties.

Original languageEnglish
Pages (from-to)29-37
Number of pages9
JournalCurrent Topics in Pharmacology
Volume18
Issue number1-2
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Selegiline
Parkinson Disease
Pharmacology
Lipid Peroxidation
Monoamine Oxidase Inhibitors
Body Weight
Messenger RNA
Therapeutics
Corpus Striatum
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Monoamine Oxidase
Dopamine
Up-Regulation
4-phenyl-1,2,3,6-tetrahydropyridine

Keywords

  • Lipid peroxidation
  • Neuroprotection
  • Parkinson's disease
  • Selegiline
  • Survivin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

A possible novel pharmacological therapy for Parkinson's disease using the pleiotropic property of Selegiline. / Ono, Shin Ichi; Sorte, Ryuji; Tokuda, Ei Ichi.

In: Current Topics in Pharmacology, Vol. 18, No. 1-2, 2014, p. 29-37.

Research output: Contribution to journalArticle

Ono, Shin Ichi ; Sorte, Ryuji ; Tokuda, Ei Ichi. / A possible novel pharmacological therapy for Parkinson's disease using the pleiotropic property of Selegiline. In: Current Topics in Pharmacology. 2014 ; Vol. 18, No. 1-2. pp. 29-37.
@article{4d78a27a5f844ea68f4dcd2ec268988c,
title = "A possible novel pharmacological therapy for Parkinson's disease using the pleiotropic property of Selegiline",
abstract = "Monoamine oxidase type B (MAO-B) inhibitors have neuroprotective properties in addition to their primary pharmacologic function. We examined the effects of selegiline, an irreversible MAO-B inhibitor, on the expression levels of survivin mRNA and lipid peroxidation in the corpus striata of 1-methyl-4-phenyl 1,2,3,6 tetrahydropyridine (MPTP)-induccd Parkinsonian roice. Mice were treated with normal saline (vehicle as control), MPTP alone (30 mg/kg of body weight), MPTP with low-dose of selegiline (0-1 mg/kg of body weight), or MPTP with high-dose of selegiline (1.0 mg/kg of body weight). A consecutive 7-day oral treatment of MPTP alone d'd not influence survivin mRNA expression. Selegiline treatment together with MPTP significantly uprcgulated survivin expression at both low- and high-doses. Interestingly, lipid Peroxidation was significantly suppressed by a low-dose of selegiline but not by a high-dose. These results suggest that selegiline has Pleiotropic effects; the upregulation effects on survivin mRNA expression are likely to be '{"}dependent from its primary pharmacological Properties (MAO-B inhibition), whereas the inhibitory effects on lipid peroxidation seem to be associated with its primary pharmacological properties. In addition to conventional dopamine supplementation therapy, selegiline might serve as a novel pharmacological therapeutic strategy for Parkinson's disease through its antiapoptotic properties via survivin induction as well as its antioxidative properties.",
keywords = "Lipid peroxidation, Neuroprotection, Parkinson's disease, Selegiline, Survivin",
author = "Ono, {Shin Ichi} and Ryuji Sorte and Tokuda, {Ei Ichi}",
year = "2014",
language = "English",
volume = "18",
pages = "29--37",
journal = "Current Topics in Pharmacology",
issn = "0972-4559",
publisher = "Research Trends",
number = "1-2",

}

TY - JOUR

T1 - A possible novel pharmacological therapy for Parkinson's disease using the pleiotropic property of Selegiline

AU - Ono, Shin Ichi

AU - Sorte, Ryuji

AU - Tokuda, Ei Ichi

PY - 2014

Y1 - 2014

N2 - Monoamine oxidase type B (MAO-B) inhibitors have neuroprotective properties in addition to their primary pharmacologic function. We examined the effects of selegiline, an irreversible MAO-B inhibitor, on the expression levels of survivin mRNA and lipid peroxidation in the corpus striata of 1-methyl-4-phenyl 1,2,3,6 tetrahydropyridine (MPTP)-induccd Parkinsonian roice. Mice were treated with normal saline (vehicle as control), MPTP alone (30 mg/kg of body weight), MPTP with low-dose of selegiline (0-1 mg/kg of body weight), or MPTP with high-dose of selegiline (1.0 mg/kg of body weight). A consecutive 7-day oral treatment of MPTP alone d'd not influence survivin mRNA expression. Selegiline treatment together with MPTP significantly uprcgulated survivin expression at both low- and high-doses. Interestingly, lipid Peroxidation was significantly suppressed by a low-dose of selegiline but not by a high-dose. These results suggest that selegiline has Pleiotropic effects; the upregulation effects on survivin mRNA expression are likely to be '"dependent from its primary pharmacological Properties (MAO-B inhibition), whereas the inhibitory effects on lipid peroxidation seem to be associated with its primary pharmacological properties. In addition to conventional dopamine supplementation therapy, selegiline might serve as a novel pharmacological therapeutic strategy for Parkinson's disease through its antiapoptotic properties via survivin induction as well as its antioxidative properties.

AB - Monoamine oxidase type B (MAO-B) inhibitors have neuroprotective properties in addition to their primary pharmacologic function. We examined the effects of selegiline, an irreversible MAO-B inhibitor, on the expression levels of survivin mRNA and lipid peroxidation in the corpus striata of 1-methyl-4-phenyl 1,2,3,6 tetrahydropyridine (MPTP)-induccd Parkinsonian roice. Mice were treated with normal saline (vehicle as control), MPTP alone (30 mg/kg of body weight), MPTP with low-dose of selegiline (0-1 mg/kg of body weight), or MPTP with high-dose of selegiline (1.0 mg/kg of body weight). A consecutive 7-day oral treatment of MPTP alone d'd not influence survivin mRNA expression. Selegiline treatment together with MPTP significantly uprcgulated survivin expression at both low- and high-doses. Interestingly, lipid Peroxidation was significantly suppressed by a low-dose of selegiline but not by a high-dose. These results suggest that selegiline has Pleiotropic effects; the upregulation effects on survivin mRNA expression are likely to be '"dependent from its primary pharmacological Properties (MAO-B inhibition), whereas the inhibitory effects on lipid peroxidation seem to be associated with its primary pharmacological properties. In addition to conventional dopamine supplementation therapy, selegiline might serve as a novel pharmacological therapeutic strategy for Parkinson's disease through its antiapoptotic properties via survivin induction as well as its antioxidative properties.

KW - Lipid peroxidation

KW - Neuroprotection

KW - Parkinson's disease

KW - Selegiline

KW - Survivin

UR - http://www.scopus.com/inward/record.url?scp=84949210282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949210282&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84949210282

VL - 18

SP - 29

EP - 37

JO - Current Topics in Pharmacology

JF - Current Topics in Pharmacology

SN - 0972-4559

IS - 1-2

ER -